Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory ...
Seeking Alpha1mon
A Dive Into Dianthus Therapeutics: Little To Move The Stock
It comes in a pre-filled pen. The candidate is a selective inhibitor of active C1s protein in the classical complement pathway. It is hoped its selective targeting of only the active form of the ...
Omeros Corporation Announces Availability on its Website of Materials Accompanying Narsoplimab Presentations at the 2025 Tandem Meetings
Omeros Corporation (Nasdaq: OMER) today announced the availability on its website of materials accompanying two presentations ...
Nature1mon
Complement driven by conformational changes
The complement proteins C3 and protease factor B have a central role in the activation pathways of the complement system. Recent advances in the structural biology of complement protein C3 ...
Business Wire8d
Omeros Corporation Announces Upcoming Presentations Detailing Outcomes of Narsoplimab Treatment for TA-TMA Under an Expanded Access Program
Omeros Corporation (Nasdaq: OMER) today announced two presentations that will be featured at the 2025 Tandem Meetings – the ...